Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Launches Methylene Blue Injection
Details : Methylene blue is a monoamine oxidase inhibitor, indicated for the treatment of methemoglobinemia.
Product Name : Methylene Blue-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2025
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ondine Recruits First Patient for US Phase 3 Trial
Details : Nasal antimicrobial photodisinfection therapy consisiting of NF-031 (methylthioninium chloride & chlorhexidine gluconate) is being evaluated for treatment of surgical site infections.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2024
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP
Details : The US FDA approved Methylene Blue Injection, USP (methylene blue). It is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.
Product Name : Methylene Blue Injection, USP
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : Methylene Blue
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Healthcare's Memorial Health University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Ondine Biomedical Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial
Details : Photodynamic Antimicrobial Chemotherapy (PACT) using methylene blue is a potential antimicrobial therapy that combines light and a photosensitizing drug, promoting a phototoxic effect on the treated cells increases membrane permeability in Candida albica...
Product Name : PACT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Healthcare's Memorial Health University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Provepharm Life Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches a New Vial Presentation
Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Product Name : ProvayBlue
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Provepharm Life Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Methylene Blue
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Zhuhai Seine Technology Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
3D Printing for Nodule Localization
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2019
Lead Product(s) : Methylene Blue
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Zhuhai Seine Technology Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Beijing Digital Precision Medicine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing Friendship Hospital | Tangshan People's Hospital | The Second Hospital of Hebei Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2018
Lead Product(s) : Methylene Blue
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Beijing Digital Precision Medicine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing Friendship Hospital | Tangshan People's Hospital | The Second Hospital of Hebei Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MEthylene Blue In Patients With Acquired Methemoglobinemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2018
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable